...
首页> 外文期刊>Scandinavian journal of primary health care. >Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: A randomized controlled trial
【24h】

Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: A randomized controlled trial

机译:吡维西南与磺胺甲唑在一般情况下短期治疗单纯性急性膀胱炎的随机对照试验

获取原文

摘要

Objective. To investigate whether short-term treatment with pivmecillinam was more effective than sulfamethizole in patients with acute uncomplicated urinary tract infection (UTI). Design. Randomized controlled trial. Setting. General practice, Denmark. Subjects. Patients (n = 167) with uncomplicated UTI confirmed by positive urine phase-contrast microscopy. Main outcome measures. Drug efficacy based on clinical and bacteriological cure. Results. Urinary symptoms disappeared first in patients treated with pivmecillinam, but after five days there was no significant difference in clinical cure rate between the two antibiotics. At the follow-up visit 7–10 days after initiation of treatment, 95.4% of patients treated with pivmecillinam and 92.6% of patients treated with sulfamethizole had no persistent cystitis symptoms (difference 2.8%, CI ?4.5%; 10.0%). Bacteriological cure was observed in 68.8% of patients randomized to pivmecillinam and in 77.9% randomized to sulfamethizole (difference ?9.2%, CI ?24.7%; 6.3%). Some 26.8% of patients randomized to pivmecillinam experienced a new UTI within 6 months after treatment compared with 18.4% of patients randomized to sulfamethizole (difference 8.4%, CI ?4.5%;21.4%). No patients developed septicaemia with urinary pathogens within one year after initial treatment. Conclusion. Patients treated with a three-day regime of pivmecillinam experienced faster relief of symptoms compared with patients treated with a three-day regime of sulfamethizole. Five days after initiation of treatment there was no significant difference in clinical and bacteriological cure between the two antibiotic regimes.
机译:目的。为了研究在急性单纯性尿路感染(UTI)患者中吡美西那南的短期治疗是否比磺胺甲咪唑更有效。设计。随机对照试验。设置。丹麦,普通科。主题。尿相衬显微镜检查阳性证实未合并尿路感染的患者(n = 167)。主要观察指标。药物疗效基于临床和细菌学治愈。结果。吡维西南治疗的患者尿液症状首先消失,但五天后,两种抗生素的临床治愈率无显着差异。在开始治疗后7-10天进行随访时,吡维西那南治疗的患者中95.4%,磺胺甲咪唑治疗的患者中92.6%没有持续性膀胱炎症状(差异为2.8%,CI≤4.5%; 10.0%)。随机分配到吡美西那南的患者中有68.8%的细菌学治愈,随机分配给磺胺甲唑的患者中有77.9%的细菌学治愈(差异为9.2%,CI为24.7%; 6.3%)。约有26.8%的患者被随机分配到吡维昔南,在治疗后6个月内发生了新的泌尿道感染,而随机分组的磺胺甲咪唑的患者为18.4%(差异8.4%,CI≤4.5%; 21.4%)。初次治疗后一年内,没有患者出现泌尿病原体败血症。结论。与接受三天磺胺甲咪唑治疗的患者相比,接受吡美昔南三天方案治疗的患者症状缓解更快。开始治疗后五天,两种抗生素方案在临床和细菌学治愈方面无显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号